Haidar M Al-Khazali, Rune H Christensen, Emil Gozalov, Zahra Hakimzadeh, Anna G Melchior, Rogelio Dominguez-Moreno, Messoud Ashina, Håkan Ashina
{"title":"P物质对健康成人头痛诱导和动脉扩张的影响。","authors":"Haidar M Al-Khazali, Rune H Christensen, Emil Gozalov, Zahra Hakimzadeh, Anna G Melchior, Rogelio Dominguez-Moreno, Messoud Ashina, Håkan Ashina","doi":"10.1177/03331024251336132","DOIUrl":null,"url":null,"abstract":"<p><p>ObjectiveTo determine whether intravenous infusion of substance P elicits headache and arterial dilation in healthy adults.MethodsIn a double-blind, placebo-controlled, two-way crossover study, we randomly allocated healthy adults to receive either substance P (1.5 pmol/kg/min) or placebo (isotonic saline) by 20-minute intravenous infusion on separate experiment days. The primary endpoint was the incidence of headache within 12 hours after the infusion. Other endpoints included the area under the curve (AUC) for headache intensity scores over the 12-hour observation period and AUC changes in the superficial temporal artery (STA) diameter from baseline to 120 minutes post-infusion.ResultsTwenty-one participants underwent randomization and completed both experiment days. Headache was reported by 15 (71%) of 21 participants following substance P, compared with two (10%) after placebo (<i>p </i>< 0.001). The AUC for headache intensity scores was significantly higher after substance P infusion than after placebo (<i>p </i>= 0.03). In addition, there was a significant STA diameter increase with substance P, compared with placebo (<i>p </i>= 0.005).ConclusionsAmong healthy adults, substance P infusion elicited headache and arterial dilation. These findings support a role for substance P in headache pathogenesis and encourage further investigation in migraine and other headache disorders. Additional research is also needed to explore new therapeutic strategies targeting substance P or its downstream signaling.Trial Registration:CT identifier: NCT06632080.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 5","pages":"3331024251336132"},"PeriodicalIF":4.6000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effects of substance P on headache induction and arterial dilation in healthy adults.\",\"authors\":\"Haidar M Al-Khazali, Rune H Christensen, Emil Gozalov, Zahra Hakimzadeh, Anna G Melchior, Rogelio Dominguez-Moreno, Messoud Ashina, Håkan Ashina\",\"doi\":\"10.1177/03331024251336132\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>ObjectiveTo determine whether intravenous infusion of substance P elicits headache and arterial dilation in healthy adults.MethodsIn a double-blind, placebo-controlled, two-way crossover study, we randomly allocated healthy adults to receive either substance P (1.5 pmol/kg/min) or placebo (isotonic saline) by 20-minute intravenous infusion on separate experiment days. The primary endpoint was the incidence of headache within 12 hours after the infusion. Other endpoints included the area under the curve (AUC) for headache intensity scores over the 12-hour observation period and AUC changes in the superficial temporal artery (STA) diameter from baseline to 120 minutes post-infusion.ResultsTwenty-one participants underwent randomization and completed both experiment days. Headache was reported by 15 (71%) of 21 participants following substance P, compared with two (10%) after placebo (<i>p </i>< 0.001). The AUC for headache intensity scores was significantly higher after substance P infusion than after placebo (<i>p </i>= 0.03). In addition, there was a significant STA diameter increase with substance P, compared with placebo (<i>p </i>= 0.005).ConclusionsAmong healthy adults, substance P infusion elicited headache and arterial dilation. These findings support a role for substance P in headache pathogenesis and encourage further investigation in migraine and other headache disorders. Additional research is also needed to explore new therapeutic strategies targeting substance P or its downstream signaling.Trial Registration:CT identifier: NCT06632080.</p>\",\"PeriodicalId\":10075,\"journal\":{\"name\":\"Cephalalgia\",\"volume\":\"45 5\",\"pages\":\"3331024251336132\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cephalalgia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/03331024251336132\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cephalalgia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03331024251336132","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/14 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Effects of substance P on headache induction and arterial dilation in healthy adults.
ObjectiveTo determine whether intravenous infusion of substance P elicits headache and arterial dilation in healthy adults.MethodsIn a double-blind, placebo-controlled, two-way crossover study, we randomly allocated healthy adults to receive either substance P (1.5 pmol/kg/min) or placebo (isotonic saline) by 20-minute intravenous infusion on separate experiment days. The primary endpoint was the incidence of headache within 12 hours after the infusion. Other endpoints included the area under the curve (AUC) for headache intensity scores over the 12-hour observation period and AUC changes in the superficial temporal artery (STA) diameter from baseline to 120 minutes post-infusion.ResultsTwenty-one participants underwent randomization and completed both experiment days. Headache was reported by 15 (71%) of 21 participants following substance P, compared with two (10%) after placebo (p < 0.001). The AUC for headache intensity scores was significantly higher after substance P infusion than after placebo (p = 0.03). In addition, there was a significant STA diameter increase with substance P, compared with placebo (p = 0.005).ConclusionsAmong healthy adults, substance P infusion elicited headache and arterial dilation. These findings support a role for substance P in headache pathogenesis and encourage further investigation in migraine and other headache disorders. Additional research is also needed to explore new therapeutic strategies targeting substance P or its downstream signaling.Trial Registration:CT identifier: NCT06632080.
期刊介绍:
Cephalalgia contains original peer reviewed papers on all aspects of headache. The journal provides an international forum for original research papers, review articles and short communications. Published monthly on behalf of the International Headache Society, Cephalalgia''s rapid review averages 5 ½ weeks from author submission to first decision.